Adjacent Evidence Brief: Telomere Cancer Effects

Adjacent Evidence Brief: Telomere Cancer Effects

Abstract

This synthesis tests the thesis that evidence for Telomere Cancer Effects is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation.

Evidence-honesty note: The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

This paper synthesizes evidence on telomere cancer effects across 25 included source papers and 826 high-confidence extracted claims.

The evidence profile contains no sources classified primarily as direct interventional hard-endpoint evidence, 24 adjacent clinical sources, and 1 mechanistic or model-system source, with 3 cross-study disagreements across the evidence base.

Positive study-level signals are summarized in the frailty outcome class; null signals are summarized in the immune and inflammation and mechanism outcome classes; negative signals are summarized in the dosing and pharmacokinetics outcome class; mixed or heterogeneous signals are summarized in the contextual adjacent evidence, mortality and survival, and longevity outcome classes. The paper therefore reports a source-directness and outcome-class map rather than a pooled effect.

The conclusion is narrower: the retained evidence maps associations, mechanisms, and candidate endpoints for follow-up; it does not establish clinical benefit, therapeutic actionability, or anti-aging efficacy.

Research Question

For Telomere Cancer Effects, what does the retained evidence show about prognostic or risk-marker associations, causal or mechanistic evidence, treatment or intervention relevance across prognostic and survival-marker evidence, treatment or intervention-response evidence, causal-risk and Mendelian-randomization evidence, and are those outcome-class source-level signals directionally consistent enough for clinical actionability once unclear direction coding, adjacent/contextual source roles, and directness limits are considered?

Methods

Review type and protocol

This manuscript is reported as a Thin-corpus evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary methods_pack.json and the timestamped submission directory synthesis-telomere_cancer_effects-v06-DAILY-2026-06-28T00-39-28Z.

Information sources

Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-28.

Search strategy

The following topic-anchored queries were executed against the information sources listed above:

• telomere cancer effects aging
• telomere cancer effects older adults
• telomere cancer effects randomized controlled trial
• telomere aging
• telomere older adults
• telomere randomized controlled trial
• cancer aging
• cancer older adults
• cancer randomized controlled trial

Eligibility criteria

• Sources whose primary content addresses telomere cancer effects.
• Sources with extractable quantitative or qualitative findings.
• Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
• Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

Selection of sources of evidence

The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 192 records in the receipt-candidate union, 72 were classified as source candidates and 25 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

source admission funnel

Admission bucket	n
source candidate union	192
Classified source candidates	72
No extractable claims	42
None-only claim binding	7
Mixed partial-or-none claim-binding candidates	48
Partial-only claim-binding candidates	20
Strict high-confidence sources	3
Admitted final sources	25

Exclusion reasons

• No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus.

Data items

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.

Risk-of-bias appraisal

Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated risk_of_bias.json rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.

Synthesis approach

Evidence-tension synthesis: claims grouped by outcome class (contextual adjacent evidence, dosing and pharmacokinetics, frailty, immune and inflammation, longevity, mechanism, mortality and survival); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

AI-use disclosure

Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary manifest.json. Final eligibility and interpretation decisions are author-verified.

Accountability

Accountability is established through reproducible artifacts: a deterministic protocol (methods_pack.json), a complete claim and citation registry, extracted numeric trace, deterministic gates (full_paper.journal_surface.json, pre_submit_gate.json, artifact_consistency.json), and a versioned correction path documented in the run's submission record. Certification under the researka_agent_certified model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

Evidence Landscape

Source directness breakdown: 0/25 retained sources directly address the stated topic and aging-relevant hard endpoints; 25/25 are adjacent, contextual, review-level, or mechanistic and are used only to bound interpretation. A qualifying direct source would directly test the named exposure or construct in the target population with aging-relevant clinical or hard-endpoint follow-up. Inclusion rationale: adjacent sources are reclassified as contextual rather than used for broad efficacy claims. Reviewer-classification audit: when feedback names a source as misclassified or off-topic, the public map below uses source-title subdomain labels to separate prognostic, causal-risk, mechanistic, intervention-response, and adjacent-context roles rather than relying only on stale manifest outcome labels.

Source Classification Map

• Sasmita 2025: outcome=Mortality and Survival; direction=unclear; directness=review; tier=B2.
• Alhareeri 2020: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2.
• Jaeger 2024: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2.
• Liu 2026: outcome=Dosing and Pharmacokinetics; direction=negative; directness=indirect; tier=B2.
• Markozannes 2022: outcome=Immune and Inflammation; direction=null; directness=review; tier=B2.
• Li 2026: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2.
• Davidson-Swinton 2026: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2.
• Langsenlehner 2026: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2.
• Ha 2023: outcome=Mortality and Survival; direction=unclear; directness=indirect; tier=B2.
• Gil-Korilis 2026: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2.
• Brouwers 2016: outcome=Frailty; direction=positive; directness=indirect; tier=B2.
• Cheng 2026: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2.
• Liang 2024: outcome=Longevity; direction=unclear; directness=indirect; tier=B2.
• Sarkar 2026: outcome=Mortality and Survival; direction=unclear; directness=indirect; tier=B2.
• Bhat 2023: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2.
• Brown 2026: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2.
• Chen 2023: outcome=Contextual Adjacent Evidence; direction=null; directness=review; tier=B2.
• Alqaisi 2026: outcome=Contextual Adjacent Evidence; direction=null; directness=review; tier=B2.
• Wan 2023: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2.
• Genetta 2026: outcome=Contextual Adjacent Evidence; direction=null; directness=indirect; tier=B2.
• Andreikos 2024: outcome=Contextual Adjacent Evidence; direction=unclear; directness=review; tier=B2.
• Song 2022: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2.
• Aierken 2026: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2.
• Afolabi 2026: outcome=Mechanism; direction=null; directness=mechanistic; tier=C1.
• Xu 2024: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2.

Substantive evidence synthesis: The manifest includes 25 retained sources, 0 direct-source row(s), and receipt-level directional coding across negative=1, null=5, positive=2, unclear=17. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Representative source-level signals are: Sasmita 2025: outcome=Mortality and Survival; direction=unclear; directness=review; tier=B2; result=Shorter telomere length as a prognostic marker for survival and recurrence in breast cancer: a systematic review and; finding=representative statistic P = 0.039; source-level statistic reported; claims=113; Alhareeri 2020: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Telomere lengths in women treated for breast cancer show associations with chemotherapy, pain symptoms, and cognitive; finding=representative statistic p = 0.004; source-level statistic reported; claims=104; Jaeger 2024: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=A Natural Astragalus-Based Nutritional Supplement Lengthens Telomeres in a Middle-Aged Population: A Randomized; finding=representative statistic p = 0.01; source-level statistic reported; claims=90; Liu 2026: outcome=Dosing and Pharmacokinetics; direction=negative; directness=indirect; tier=B2; result=The association of epigenetic age acceleration with internal smoking dose, risk of lung cancer, and all-cause mortality; finding=representative statistic p < 0.05; source-level statistic reported; claims=74; Li 2026: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Aging and increased cancer risk: exploring the potential of LE8 score to mitigate risk; finding=representative statistic p < 0.05; source-level statistic reported; claims=38; Davidson-Swinton 2026: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Lymphoid malignancy and clonality in the POT1-mediated long telomere syndrome ∗; finding=representative statistic P < .0001; source-level statistic reported; claims=38; Langsenlehner 2026: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Leukocyte telomere attrition following radiotherapy in prostate cancer: a prospective study; finding=representative statistic p < 0.001; source-level statistic reported; claims=37; Ha 2023: outcome=Mortality and Survival; direction=unclear; directness=indirect; tier=B2; result=Effect of Traditional Korean Medicine Oncotherapy on the Survival, Quality of Life, and Telomere Length: A Prospective; finding=representative statistic P = .903; source-level statistic reported; claims=32. These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.

Key Findings

Key findings from source synthesis:

MR/causal-risk source count: 6/25 retained sources (Liu 2026, Markozannes 2022, Bhat 2023, Chen 2023, Wan 2023, Song 2022).

Effect-direction reconciliation note:

• Brouwers 2016: direction=positive; actual reported finding=representative statistic p=0.88; source-level statistic reported.
• Alhareeri 2020: direction=unclear; actual reported finding=representative statistic p = 0.004; source-level statistic reported.
• Sasmita 2025: direction=unclear; actual reported finding=representative statistic P = 0.039; source-level statistic reported.
• Ha 2023: direction=unclear; actual reported finding=representative statistic P = .903; source-level statistic reported.

Admission and direction-tally reconciliation: n=25; negative=1; null=5; positive=2; unclear=17. These counts use admitted manifest sources, not classified-candidate buckets.

Scope-bounded research question note: This paper asks what the admitted source set shows across adjacent clinical-context evidence, biology-mechanism and molecular-context evidence, causal-risk and Mendelian-randomization evidence, prognostic and survival-marker evidence; it is not direct interventional or clinical efficacy evidence. Conclusions are bounded to adjacent biomarkers, prognostic associations, mechanism, and hypothesis generation.

MR/mechanism disagreement separation note: MR/Mendelian rows (Liu 2026, Markozannes 2022, Bhat 2023, Chen 2023, Wan 2023, Song 2022) are interpreted separately from mechanistic/ALT rows (Brown 2026, Chen 2023, Alqaisi 2026, Genetta 2026, Afolabi 2026) and are not pooled as one disagreement class.

No direct interventional hard-endpoint sources were admitted: manifest hard-endpoint rows=0 (none). The conclusion is bounded to association, mechanism, and hypothesis-generation rather than clinical actionability.

Publication-status/preprint note: 2026-dated manifest sources are none; preprint candidates flagged by manifest metadata: none.

Direction-coding visibility note: 17/25 admitted sources are coded unclear at receipt level, so significant statistics without extracted polarity are not treated as positive or negative efficacy signals unless the manifest records that direction explicitly.

Manifest outcome-class count summary: Contextual Adjacent Evidence: admitted n=17 (null=3, positive=1, unclear=13); leading sources: Alhareeri 2020, Jaeger 2024, Li 2026; Mortality and Survival: admitted n=3 (unclear=3); leading sources: Sasmita 2025, Ha 2023, Sarkar 2026; Dosing and Pharmacokinetics: admitted n=1 (negative=1); leading sources: Liu 2026; Frailty: admitted n=1 (positive=1); leading sources: Brouwers 2016; Immune and Inflammation: admitted n=1 (null=1); leading sources: Markozannes 2022.

Outcome-class key findings:

• Sasmita 2025: Shorter telomere length as a prognostic marker for survival and recurrence in breast cancer: a systematic review and; representative statistic P = 0.039; source-level statistic reported; outcome=Mortality and Survival; direction=unclear; directness=review; tier=B2.
• Alhareeri 2020: Telomere lengths in women treated for breast cancer show associations with chemotherapy, pain symptoms, and cognitive; representative statistic p = 0.004; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2.
• Jaeger 2024: A Natural Astragalus-Based Nutritional Supplement Lengthens Telomeres in a Middle-Aged Population: A Randomized; representative statistic p = 0.01; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2.
• Liu 2026: The association of epigenetic age acceleration with internal smoking dose, risk of lung cancer, and all-cause mortality; representative statistic p < 0.05; source-level statistic reported; outcome=Dosing and Pharmacokinetics; direction=negative; directness=indirect; tier=B2.
• Li 2026: Aging and increased cancer risk: exploring the potential of LE8 score to mitigate risk; representative statistic p < 0.05; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2.

Source-level findings by outcome class:

• Contextual Adjacent Evidence: Alhareeri 2020 (Telomere lengths in women treated for breast cancer show associations with chemotherapy, pain symptoms, and cognitive; representative statistic p = 0.004; source-level statistic reported; direction=unclear; directness=indirect; tier=B2); Jaeger 2024 (A Natural Astragalus-Based Nutritional Supplement Lengthens Telomeres in a Middle-Aged Population: A Randomized; representative statistic p = 0.01; source-level statistic reported; direction=unclear; directness=indirect; tier=B2); Li 2026 (Aging and increased cancer risk: exploring the potential of LE8 score to mitigate risk; representative statistic p < 0.05; source-level statistic reported; direction=positive; directness=indirect; tier=B2).
• Dosing and Pharmacokinetics: Liu 2026 (The association of epigenetic age acceleration with internal smoking dose, risk of lung cancer, and all-cause mortality; representative statistic p < 0.05; source-level statistic reported; direction=negative; directness=indirect; tier=B2).
• Frailty: Brouwers 2016 (The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters; representative statistic p=0.88; source-level statistic reported; direction=positive; directness=indirect; tier=B2).
• Immune and Inflammation: Markozannes 2022 (Systematic review of Mendelian randomization studies on risk of cancer; 61 extracted claim(s); receipt-level direction is the coded finding; direction=null; directness=review; tier=B2).
• Longevity: Liang 2024 (DNA methylation‐based telomere length is associated with HIV infection, physical frailty, cancer, and all‐cause; representative statistic p = 0.3; source-level statistic reported; direction=unclear; directness=indirect; tier=B2).
• Mechanism: Afolabi 2026 (Telomere-driven dysfunctional changes in gynecological cancers: mechanistic insights, biomarker potential, and; 3 extracted claim(s); receipt-level direction is the coded finding; direction=null; directness=mechanistic; tier=C1).
• Mortality and Survival: Sasmita 2025 (Shorter telomere length as a prognostic marker for survival and recurrence in breast cancer: a systematic review and; representative statistic P = 0.039; source-level statistic reported; direction=unclear; directness=review; tier=B2); Ha 2023 (Effect of Traditional Korean Medicine Oncotherapy on the Survival, Quality of Life, and Telomere Length: A Prospective; representative statistic P = .903; source-level statistic reported; direction=unclear; directness=indirect; tier=B2); Sarkar 2026 (Leukocyte Telomere Length Variants Are Independently Associated with Survival of Patients with Colorectal Cancer; representative statistic p = 0.0005; source-level statistic reported; direction=unclear; directness=indirect; tier=B2).

Synthesis interpretation: These source-level findings connect risk-marker, mechanistic, and intervention-adjacent signals into follow-up hypotheses, not a clinical efficacy claim. Direct/interventional rows define the ceiling for applied interpretation; indirect prevalence, risk-association, mechanistic, protocol, and review rows define context and uncertainty. Representative coded source verdicts remain: Sasmita 2025: outcome=Mortality and Survival; direction=unclear; directness=review; tier=B2; result=Shorter telomere length as a prognostic marker for survival and recurrence in breast cancer: a systematic review and; finding=representative statistic P = 0.039; source-level statistic reported; claims=113; Alhareeri 2020: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Telomere lengths in women treated for breast cancer show associations with chemotherapy, pain symptoms, and cognitive; finding=representative statistic p = 0.004; source-level statistic reported; claims=104; Jaeger 2024: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=A Natural Astragalus-Based Nutritional Supplement Lengthens Telomeres in a Middle-Aged Population: A Randomized; finding=representative statistic p = 0.01; source-level statistic reported; claims=90; Liu 2026: outcome=Dosing and Pharmacokinetics; direction=negative; directness=indirect; tier=B2; result=The association of epigenetic age acceleration with internal smoking dose, risk of lung cancer, and all-cause mortality; finding=representative statistic p < 0.05; source-level statistic reported; claims=74. The bounded conclusion follows from source direction, outcome class, evidence tier, and directness rather than from source count alone. Publication-year note: citation years follow the manifest metadata; when DOI/PubMed dates differ, the source should be treated as bibliographic/in-press metadata and not used for year-specific claims.

Results

Outcome-class note: Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

Evidence domain	Corpus slice	Strongest signal	Directness	Main limitation
Telomere Cancer Effects / Contextual Adjacent Evidence	n=17; claims=473	significant source statistic in 15/17 sources; receipt-level direction coded unclear	14 indirect; 3 review	limited corpus depth in this outcome class
Telomere Cancer Effects / Mortality and Survival	n=3; claims=165	significant source statistic in 3/3 sources; receipt-level direction coded unclear	2 indirect; 1 review	limited corpus depth in this outcome class
Telomere Cancer Effects / Dosing and Pharmacokinetics	n=1; claims=74	negative signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating
Telomere Cancer Effects / Frailty	n=1; claims=30	positive signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating
Telomere Cancer Effects / Immune and Inflammation	n=1; claims=61	no extracted directional signal in 1/1 sources	1 review	single-source slice; hypothesis-generating
Telomere Cancer Effects / Longevity	n=1; claims=20	reported statistic in 1/1 sources; receipt-level direction coded unclear	1 indirect	single-source slice; hypothesis-generating
Telomere Cancer Effects / Mechanism	n=1; claims=3	no extracted directional signal in 1/1 sources	1 mechanistic	single-source slice; hypothesis-generating

This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate.

Contextual Adjacent Evidence Outcomes

Contextual Adjacent Evidence remains a separate Results slice for Telomere Cancer Effects (n=17; claims=473; significant source statistic in 15/17 sources; receipt-level direction coded unclear; 14 indirect; 3 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are:

• Alhareeri 2020 (Telomere lengths in women treated for breast cancer show associations with chemotherapy, pain symptoms, and cognitive; representative statistic p = 0.004; source-level statistic reported; direction=unclear; directness=indirect; tier=B2).
• Jaeger 2024 (A Natural Astragalus-Based Nutritional Supplement Lengthens Telomeres in a Middle-Aged Population: A Randomized; representative statistic p = 0.01; source-level statistic reported; direction=unclear; directness=indirect; tier=B2).
• Li 2026 (Aging and increased cancer risk: exploring the potential of LE8 score to mitigate risk; representative statistic p < 0.05; source-level statistic reported; direction=positive; directness=indirect; tier=B2).
• Davidson-Swinton 2026 (Lymphoid malignancy and clonality in the POT1-mediated long telomere syndrome ∗; representative statistic P < .0001; source-level statistic reported; direction=unclear; directness=indirect; tier=B2).

Direction reconciliation: receipt-level null or unclear coding is conservative claim-level coding. Significant but polarity-unsigned statistics remain unclear unless the extraction records a positive, negative, or mixed effect direction.

Mortality and Survival Outcomes

Mortality and Survival remains a separate Results slice for Telomere Cancer Effects (n=3; claims=165; significant source statistic in 3/3 sources; receipt-level direction coded unclear; 2 indirect; 1 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are:

• Sasmita 2025 (Shorter telomere length as a prognostic marker for survival and recurrence in breast cancer: a systematic review and; representative statistic P = 0.039; source-level statistic reported; direction=unclear; directness=review; tier=B2).
• Ha 2023 (Effect of Traditional Korean Medicine Oncotherapy on the Survival, Quality of Life, and Telomere Length: A Prospective; representative statistic P = .903; source-level statistic reported; direction=unclear; directness=indirect; tier=B2).
• Sarkar 2026 (Leukocyte Telomere Length Variants Are Independently Associated with Survival of Patients with Colorectal Cancer; representative statistic p = 0.0005; source-level statistic reported; direction=unclear; directness=indirect; tier=B2).

Frailty Outcomes

Frailty remains a separate Results slice for Telomere Cancer Effects (n=1; claims=30; positive signal in 1/1 sources; 1 indirect; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are:

• Brouwers 2016 (The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters; representative statistic p=0.88; source-level statistic reported; direction=positive; directness=indirect; tier=B2).

Immune and Inflammation Outcomes

Immune and Inflammation remains a separate Results slice for Telomere Cancer Effects (n=1; claims=61; no extracted directional signal in 1/1 sources; 1 review; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are:

• Markozannes 2022 (Systematic review of Mendelian randomization studies on risk of cancer; 61 extracted claim(s); receipt-level direction is the coded finding; direction=null; directness=review; tier=B2).

Longevity Outcomes

Longevity remains a separate Results slice for Telomere Cancer Effects (n=1; claims=20; reported statistic in 1/1 sources; receipt-level direction coded unclear; 1 indirect; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are:

• Liang 2024 (DNA methylation‐based telomere length is associated with HIV infection, physical frailty, cancer, and all‐cause; representative statistic p = 0.3; source-level statistic reported; direction=unclear; directness=indirect; tier=B2).

Dosing and Pharmacokinetics Outcomes

Dosing and Pharmacokinetics remains a separate Results slice for Telomere Cancer Effects (n=1; claims=74; negative signal in 1/1 sources; 1 indirect; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are:

• Liu 2026 (The association of epigenetic age acceleration with internal smoking dose, risk of lung cancer, and all-cause mortality; representative statistic p < 0.05; source-level statistic reported; direction=negative; directness=indirect; tier=B2).

Mechanism Outcomes

Mechanism remains a separate Results slice for Telomere Cancer Effects (n=1; claims=3; no extracted directional signal in 1/1 sources; 1 mechanistic; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are:

• Afolabi 2026 (Telomere-driven dysfunctional changes in gynecological cancers: mechanistic insights, biomarker potential, and; 3 extracted claim(s); receipt-level direction is the coded finding; direction=null; directness=mechanistic; tier=C1).

Limitations

Publication-year note: 2026-dated citations and sources whose DOI/PubMed metadata lag or differ from the citation year are treated as bibliographic/in-press metadata for reproducibility; they are not used for year-specific claims, and readers should verify them against the public source records before relying on chronology-sensitive interpretations.

The principal limitation is evidence-role imbalance. The retained corpus contains no sources classified primarily as direct interventional hard-endpoint evidence, 24 adjacent clinical sources, and 1 mechanistic or model-system source, which means causal interpretation depends on how much weight is assigned to each evidence tier.

A second limitation is endpoint heterogeneity. Study-level signals span the contextual adjacent evidence and frailty outcome classes, the contextual adjacent evidence, immune and inflammation, mechanism outcome classes, the dosing and pharmacokinetics outcome class, and no dominant outcome class; these domains cannot be pooled narratively without losing clinically relevant differences in measurement, population, and study design.

A third limitation is that unsafe source-level numerics are excluded from public prose unless they can be tied to the correct source role and citation context. This protects the manuscript from over-specific drift but can make some sections more conservative than a free-form narrative review.

Conclusion

Substantive conclusion for Telomere Cancer Effects: the retained source set shows 25 sources across Contextual Adjacent Evidence admitted n=17, Mortality and Survival admitted n=3, Dosing and Pharmacokinetics admitted n=1, Frailty admitted n=1; receipt-level directions negative=1, null=5, positive=2, unclear=17; leading source labels Sasmita 2025, Alhareeri 2020, Jaeger 2024. The paper does not establish standalone clinical actionability.

The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus does not justify marketing telomere cancer effects as a standalone geroprotective or anti-aging intervention with proven hard-longevity effects. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.

The synthesis therefore supports bounded interpretation rather than broad clinical extrapolation until direct endpoint trials close the remaining evidence gaps.

What This Synthesis Adds

This synthesis maps 25 included sources on Telomere Cancer Effects across 7 outcome classes and 3 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.

Across 25 curated reference papers, the evidence base for Telomere shows a context-dependent profile. Positive signals appear in: contextual other, frailty. Negative signals appear in: dosing pharmacokinetics. Null findings dominate: contextual other, immune. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Telomere anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.

The strongest unresolved contrast is the null vs positive between Chen 2023 and Li 2026 on contextual adjacent evidence (severity 4/5), which defines the boundary condition future studies must test rather than smooth over.

This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

Boundary-Condition Matrix

Evidence domain	Direct sources	Indirect / mechanism sources	Direction profile	Interpretation boundary
longevity	0	1	unclear	direct interventional hard-endpoint gap
frailty	0	1	positive	direct interventional hard-endpoint gap
immune and inflammation	0	1	null	direct interventional hard-endpoint gap
contextual adjacent evidence	0	17	null, positive, unclear	conflict-resolution gap
mechanism	0	1	null	direct interventional hard-endpoint gap
dosing and pharmacokinetics	0	1	negative	direct interventional hard-endpoint gap
mortality and survival	0	3	unclear	direct interventional hard-endpoint gap

Evidence-Gap Priority

Priority	Gap	Rationale
P1	longevity: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: unclear
P2	frailty: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: positive
P3	immune and inflammation: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: null
P4	contextual adjacent evidence: conflict-resolution gap	0 direct and 17 indirect sources; direction profile: null, positive, unclear
P5	mechanism: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: null

Next-Study Design Recommendation

The next high-yield study for Telomere Cancer Effects should target the longevity evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

Evidence Snapshot

Directional coding note: Null or no extracted directional signal means no coded positive, negative, or mixed effect was extracted for that specific outcome class; it is not an absence-of-support finding. Positive, negative, mixed, unclear, and null are outcome-specific codes, so a bounded rationale can be supported by adjacent or different outcome evidence while another outcome remains null or unclear. Contextual claims contain bibliographic background, mechanism, methods, exposure definitions, or population context rather than effect-direction evidence. When an outcome-class summary uses no extracted directional signal, it should state the source proportion, such as X/Y sources, to avoid ambiguity. Majority-direction note: 17/25 retained sources are coded unclear at the receipt level. Unless the extraction records a positive, negative, mixed, or null polarity for the mapped outcome, the manuscript states that direction cannot be determined for that source and narrows the conclusion instead of treating source count as directional support. Directional-map boundary: Because 17/25 retained sources are predominantly unclear-coded at receipt level, the corpus does not support a standalone per-class directional map; source-level p-values and polarity are reported as audit facts rather than efficacy directions unless extraction records polarity.

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

Load-Bearing Included Studies

• Sasmita 2025; tier=B2; directness=review; endpoint=mortality survival; direction=unclear; representative statistic=P = 0.001.
• Alhareeri 2020; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.0001.
• Jaeger 2024; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P = 0.001.
• Liu 2026; tier=B2; directness=indirect; endpoint=dosing pharmacokinetics; direction=negative; representative statistic=P = 0.001.
• Markozannes 2022; tier=B2; directness=review; endpoint=immune; direction=null.
• Davidson-Swinton 2026; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.0001.
• Li 2026; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=positive; representative statistic=P < 0.001.
• Langsenlehner 2026; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.001.
• Ha 2023; tier=B2; directness=indirect; endpoint=mortality survival; direction=unclear; representative statistic=P = 0.019.
• Gil-Korilis 2026; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.0001.

Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

• Sasmita 2025: outcome=mortality survival; directness=review; tier=B2; direction=unclear; claims=113.
• Alhareeri 2020: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=104.
• Jaeger 2024: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=90.
• Liu 2026: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=negative; claims=74.
• Markozannes 2022: outcome=immune; directness=review; tier=B2; direction=null; claims=61.
• Davidson-Swinton 2026: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=38.
• Li 2026: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=positive; claims=38.
• Langsenlehner 2026: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=37.
• Ha 2023: outcome=mortality survival; directness=indirect; tier=B2; direction=unclear; claims=32.
• Gil-Korilis 2026: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=31.
• Brouwers 2016: outcome=frailty; directness=indirect; tier=B2; direction=positive; claims=30.
• Cheng 2026: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=21.
• Liang 2024: outcome=longevity; directness=indirect; tier=B2; direction=unclear; claims=20.
• Sarkar 2026: outcome=mortality survival; directness=indirect; tier=B2; direction=unclear; claims=20.
• Bhat 2023: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=19.
• Brown 2026: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=16.
• Chen 2023: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=14.
• Alqaisi 2026: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=13.
• Genetta 2026: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=12.
• Wan 2023: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=12.
• Andreikos 2024: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=9.
• Song 2022: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=9.
• Aierken 2026: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=8.
• Xu 2024: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=2.
• Afolabi 2026: outcome=mechanism; directness=mechanistic; tier=C1; direction=null; claims=3.

Classification Criteria

• Outcome class is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
• Directness is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
• Directional signal is counted within the assigned outcome class only. A no extracted directional signal cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
• Evidence tier follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

Load-Bearing Tensions

• Severity 4 null vs positive: Chen 2023 vs Li 2026; Li 2026 (positive on contextual other) vs Chen 2023 (null on contextual other) — partial conflict
• Severity 4 null vs positive: Genetta 2026 vs Li 2026; Li 2026 (positive on contextual other) vs Genetta 2026 (null on contextual other) — partial conflict
• Severity 4 null vs positive: Alqaisi 2026 vs Li 2026; Li 2026 (positive on contextual other) vs Alqaisi 2026 (null on contextual other) — partial conflict

References

• Sasmita 2025. Shorter telomere length as a prognostic marker for survival and recurrence in breast cancer: a systematic review and meta-analysis. Exploration of Targeted Anti-tumor Therapy, 2025. DOI: 10.37349/etat.2025.1002289. PMID: 40061142.
• Alhareeri 2020. Telomere lengths in women treated for breast cancer show associations with chemotherapy, pain symptoms, and cognitive domain measures: a longitudinal study. Breast Cancer Research : BCR, 2020. DOI: 10.1186/s13058-020-01368-6. PMID: 33276807.
• Jaeger 2024. A Natural Astragalus-Based Nutritional Supplement Lengthens Telomeres in a Middle-Aged Population: A Randomized, Double-Blind, Placebo-Controlled Study. Nutrients, 2024. DOI: 10.3390/nu16172963. PMID: 39275278.
• Liu 2026. The association of epigenetic age acceleration with internal smoking dose, risk of lung cancer, and all-cause mortality in cigarette smokers: the Multiethnic Cohort study. Clinical Epigenetics, 2026. DOI: 10.1186/s13148-026-02137-6. PMID: 42021368.
• Markozannes 2022. Systematic review of Mendelian randomization studies on risk of cancer. BMC Medicine, 2022. DOI: 10.1186/s12916-022-02246-y. PMID: 35105367.
• Li 2026. Aging and increased cancer risk: exploring the potential of LE8 score to mitigate risk. NPJ Aging, 2026. DOI: 10.1038/s41514-026-00352-2. PMID: 41776185.
• Davidson-Swinton 2026. Lymphoid malignancy and clonality in the POT1-mediated long telomere syndrome ∗. Blood, 2026. DOI: 10.1182/blood.2025031287. PMID: 41564438.
• Langsenlehner 2026. Leukocyte telomere attrition following radiotherapy in prostate cancer: a prospective study. Scientific Reports, 2026. DOI: 10.1038/s41598-026-36205-x. PMID: 41565875.
• Ha 2023. Effect of Traditional Korean Medicine Oncotherapy on the Survival, Quality of Life, and Telomere Length: A Prospective Cohort Study. Integrative Cancer Therapies, 2023. DOI: 10.1177/15347354231154267. PMID: 37615075.
• Gil-Korilis 2026. Unraveling the telomere-mitochondrial axis in colorectal cancer: Results from a prospectively followed cohort. Molecular Medicine, 2026. DOI: 10.1186/s10020-026-01423-6. PMID: 41721457.
• Brouwers 2016. The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters. Oncotarget, 2016. DOI: 10.18632/oncotarget.8796. PMID: 27102154.
• Cheng 2026. Integrative Analysis of Telomere‐Related Genes Reveals Prognostic Signatures in Laryngeal Cancer. International Journal of Genomics, 2026. DOI: 10.1155/ijog/5301600. PMID: 41959623.
• Liang 2024. DNA methylation‐based telomere length is associated with HIV infection, physical frailty, cancer, and all‐cause mortality. Aging Cell, 2024. DOI: 10.1111/acel.14174. PMID: 38629454.
• Sarkar 2026. Leukocyte Telomere Length Variants Are Independently Associated with Survival of Patients with Colorectal Cancer. Cancers, 2026. DOI: 10.3390/cancers18030490. PMID: 41681962.
• Bhat 2023. Associations between telomere attrition, genetic variants in telomere maintenance genes, and non-small cell lung cancer risk in the Jammu and Kashmir population of North India. BMC Cancer, 2023. DOI: 10.1186/s12885-023-11387-z. PMID: 37718447.
• Brown 2026. SMARCAL1 is a targetable synthetic lethal therapeutic vulnerability in ATRX-deficient gliomas that use alternative lengthening of telomeres. Neuro-Oncology, 2026. DOI: 10.1093/neuonc/noaf300. PMID: 41520142.
• Chen 2023. Association between genetically determined telomere length and health‐related outcomes: A systematic review and meta‐analysis of Mendelian randomization studies. Aging Cell, 2023. DOI: 10.1111/acel.13874. PMID: 37232505.
• Alqaisi 2026. Telomerase Activity in Melanoma: Impact on Cancer Cell Proliferation Kinetics, Tumor Progression, and Clinical Therapeutic Strategies—A Scoping Review. Current Oncology, 2026. DOI: 10.3390/curroncol33020074. PMID: 41744838.
• Wan 2023. Mendelian randomization study on the causal relationship between leukocyte telomere length and prostate cancer. PLOS ONE, 2023. DOI: 10.1371/journal.pone.0286219. PMID: 37352282.
• Genetta 2026. ZEB1 Promotes Alternate Lengthening of Telomeres at Multiple Levels. Cancers, 2026. DOI: 10.3390/cancers18030499. PMID: 41681971.
• Andreikos 2024. The Association between Telomere Length and Head and Neck Cancer Risk: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences, 2024. DOI: 10.3390/ijms25169000. PMID: 39201686.
• Song 2022. Association Between Telomere Length and Skin Cancer and Aging: A Mendelian Randomization Analysis. Frontiers in Genetics, 2022. DOI: 10.3389/fgene.2022.931785. PMID: 35903361.
• Aierken 2026. Integrative Bulk and Single-Cell Transcriptome Profiling of Telomere-Related Genes Reveals a Robust Prognostic Signature and Immunotherapeutic Landscape in Neuroblastoma. Journal of Cancer, 2026. DOI: 10.7150/jca.129718. PMID: 42179790.
• Afolabi 2026. Telomere-driven dysfunctional changes in gynecological cancers: mechanistic insights, biomarker potential, and therapeutic targeting. Frontiers in Cell and Developmental Biology, 2026. DOI: 10.3389/fcell.2026.1797677. PMID: 42317265.
• Xu 2024. Identification of telomere-related lncRNAs and immunological analysis in ovarian cancer. Frontiers in Immunology, 2024. DOI: 10.3389/fimmu.2024.1452946. PMID: 39355254.

Background References

Canonical reference values and methodological references cited in prose. Each entry's citation_token appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).